Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors
Public ClinicalTrials.gov record NCT07444814. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1 First-in-Human Study of PTK7-Directed Antibody Drug Conjugate HWK-007 in Participants With Advanced Solid Tumors
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
HWK-007-101 is a multicenter, open-label, first-in-human (FIH) Phase 1 study evaluating HWK-007, a protein tyrosine kinase 7 (PTK7)-targeted antibody drug conjugate (ADC), in adult participants with advanced or metastatic solid tumors known to be expressing PTK7. The study employs a sequential dose escalation and dose expansion design without a control group.
Study identification
- NCT ID
- NCT07444814
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 226 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 18, 2025
- Primary completion
- Sep 30, 2028
- Completion
- Nov 30, 2028
- Last update posted
- Aug 4, 2026
2025 – 2028
United States locations
- U.S. sites
- 12
- U.S. states
- 10
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Arkansas | Little Rock | Arkansas | 72205-7199 | Recruiting |
| UCLA - Hematology/Oncology Clinical Research Unit | Los Angeles | California | 90095 | Not yet recruiting |
| St. Francis Medical Center (OSF Healthcare) | Peoria | Illinois | 61637 | Recruiting |
| START - Midwest | Grand Rapids | Michigan | 49546 | Recruiting |
| Hackensack University Medical Center - John Theurer Cancer Center | Hackensack | New Jersey | 07601 | Recruiting |
| Roswell Park Comprehensive Care Center | Buffalo | New York | 14263 | Recruiting |
| University Hospital - Cleveland Medical Center | Cleveland | Ohio | 44106 | Recruiting |
| NEXT Oncology - Austin | Austin | Texas | 78758 | Recruiting |
| NEXT - Oncology - Houston | Houston | Texas | 77054 | Recruiting |
| START - San Antonio | San Antonio | Texas | 78229 | Recruiting |
| NEXT Oncology - Virginia Cancer Specialists | Fairfax | Virginia | 22031 | Recruiting |
| Fred Hutchinson Cancer Center | Seattle | Washington | 98109 | Not yet recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07444814, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 4, 2026 · Synced Sep 13, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07444814 live on ClinicalTrials.gov.